At least seven drugmakers, including GlaxoSmithKline (GSK), Merck (MRK), and Sanofi (SNY), are expected to announce price cuts with Trump in exchange for incentives such as tariff relief and faster FDA reviews through priority vouchers, The Washington Post’s Dan Diamond reports. The deals, following similar announcements with other companies including Pfizer (PFE), could significantly boost revenues by expediting drug approvals while offering discounted prices to the government and consumers via TrumpRx.gov, according to the report. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), Johnson & Johnson (JNJ), Novartis (NVS), and Roche (RHHBY).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson announces FDA approval of TRUFILL n-BCA Liquid Embolic System
- Johnson & Johnson price target raised to $240 from $213 at Goldman Sachs
- Johnson and Johnson’s Rybrevant Faspro combination in NSCLC approved by FDA
- Johnson & Johnson announces FDA approved Rybrevant in NSCLC patients
- 3 Best ETFs to Invest In, According to AI Analyst, 12/17/2025